The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy

Neurobiology of Disease

Volumn 33, Issue 1, 2009, Pages 96-103

  Kroner, Antje ^a   Schwab, Nicholas ^a   Ip, Chi Wang ^a   Sommer, Claudia ^a   Wessig, Carsten ^a   Wiendl, Heinz ^a   Martini, Rudolf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adaptive immune system; Charcot Marie Tooth disease; Macrophages; Myelin; Schwann cell; T lymphocytes

Indexed keywords

MYELIN; PROGRAMMED DEATH 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DEMYELINATION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; GENETICS; HISTOLOGY; HOMEOSTASIS; IMMUNOREGULATION; MOTOR COORDINATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSATION; T LYMPHOCYTE ACTIVATION; WALKING;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CHARCOT-MARIE-TOOTH DISEASE; CHIMERA; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GAIT APRAXIA; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PERIPHERAL NERVOUS SYSTEM DISEASES; QUADRICEPS MUSCLE; SCIATIC NERVE; SPINAL NERVE ROOTS; STATISTICS, NONPARAMETRIC; TOUCH;

EID: 57649096271     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.09.021     Document Type: Article

References (36)

1. Berger P., Niemann A., and Suter U. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54 (2006) 243-257
2. Carenini S., Maurer M., Werner A., Blazyca H., Toyka K.V., Schmid C.D., Raivich G., and Martini R. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J. Cell. Biol. 152 (2001) 301-308
3. Carter L.L., Leach M.W., Azoitei M.L., Cui J., Pelker J.W., Jussif J., Benoit S., Ireland G., Luxenberg D., Askew G.R., Milarski K.L., Groves C., Brown T., Carito B.A., Percival K., Carreno B.M., Collins M., and Marusic S. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182 (2007) 124-134
4. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
5. Fife B.T., Guleria I., Gubbels Bupp M., Eagar T.N., Tang Q., Bour-Jordan H., Yagita H., Azuma M., Sayegh M.H., and Bluestone J.A. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203 (2006) 2737-2747
6. Fischer S., Kleinschnitz C., Muller M., Kobsar I., Ip C.W., Rollins B., and Martini R. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol. Cell. Neurosci. 37 (2008) 359-366
7. Giese K.P., Martini R., Lemke G., Soriano P., and Schachner M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71 (1992) 565-576
8. Grabie N., Gotsman I., DaCosta R., Pang H., Stavrakis G., Butte M.J., Keir M.E., Freeman G.J., Sharpe A.H., and Lichtman A.H. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116 (2007) 2062-2071
9. Ip C.W., Kroner A., Bendszus M., Leder C., Kobsar I., Fischer S., Wiendl H., Nave K.A., and Martini R. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J. Neurosci. 26 (2006) 8206-8216
10. Ip C.W., Kroner A., Fischer S., Berghoff M., Kobsar I., Maurer M., and Martini R. Role of immune cells in animal models for inherited peripheral neuropathies. Neuromol. Med. 8 (2006) 175-190
11. Ip C.W., Kroner A., Crocker P.R., Nave K.A., and Martini R. Sialoadhesin deficiency ameliorates myelin degeneration and axonopathic changes in the CNS of PLP overexpressing mice. Neurobiol. Dis. 25 (2007) 105-111
12. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., Koulmanda M., Freeman G.J., Sayegh M.H., and Sharpe A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203 (2006) 883-895
13. Kobsar I., Berghoff M., Samsam M., Wessig C., Maurer M., Toyka K.V., and Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126 (2003) 804-813
14. Kroner A., Grimm A., Johannssen K., Maurer M., and Wiendl H. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. Hum. Immunol. 68 (2007) 422-425
15. Kunkel-Bagden E., Dai H.N., and Bregman B.S. Methods to assess the development and recovery of locomotor function after spinal cord injury in rats. Exp. Neurol. 119 (1993) 153-164
16. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A.H., and Freeman G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001) 261-268
17. Leder C., Schwab N., Ip C.W., Kroner A., Nave K.A., Dornmair K., Martini R., and Wiendl H. Clonal expansions of pathogenic CD8+ effector cells in the CNS of myelin mutant mice. Mol. Cell. Neurosci. 36 (2007) 416-424
18. Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., and Sharpe A.H. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33 (2003) 2706-2716
19. Magnus T., Schreiner B., Korn T., Jack C., Guo H., Antel J., Ifergan I., Chen L., Bischof F., Bar-Or A., and Wiendl H. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J. Neurosci. 25 (2005) 2537-2546
20. Martini R., and Toyka K.V. Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol. 3 (2004) 457-465
21. Martini R., Zielasek J., Toyka K.V., Giese K.P., and Schachner M. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat. Genet. 11 (1995) 281-286
22. Maurer M., Schmid C.D., Bootz F., Zielasek J., Toyka K.V., Oehen S., and Martini R. Bone marrow transfer from wild-type mice reverts the beneficial effect of genetically mediated immune deficiency in myelin mutants. Mol. Cell. Neurosci. 17 (2001) 1094-1101
23. Niemann A., Berger P., and Suter U. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromol. Med. 8 (2006) 217-242
24. Nishimura H., Minato N., Nakano T., and Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10 (1998) 1563-1572
25. Okazaki T., and Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27 (2006) 195-201
26. Okazaki T., and Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19 (2007) 813-824
27. Okazaki T., Iwai Y., and Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14 (2002) 779-782
28. Ortler S., Leder C., Mittelbronn M., Zozulya A.L., Knolle P.A., Chen L., Kroner A., and Wiendl H. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur. J. Immunol. 38 (2008) 1734-1744
29. Pennuto M., Tinelli E., Malaguti M., Del Carro U., D'Antonio M., Ron D., Quattrini A., Feltri M.L., and Wrabetz L. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 57 (2008) 393-405
30. Salama A.D., Chitnis T., Imitola J., Ansari M.J., Akiba H., Tushima F., Azuma M., Yagita H., Sayegh M.H., and Khoury S.J. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198 (2003) 71-78
31. Samsam M., Mi W., Wessig C., Zielasek J., Toyka K.V., Coleman M.P., and Martini R. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J. Neurosci. 23 (2003) 2833-2839
32. Schmid C.D., Stienekemeier M., Oehen S., Bootz F., Zielasek J., Gold R., Toyka K.V., Schachner M., and Martini R. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J. Neurosci. 20 (2000) 729-735
33. Sharpe A.H., Wherry E.J., Ahmed R., and Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8 (2007) 239-245
34. Shy M.E., Arroyo E., Sladky J., Menichella D., Jiang H., Xu W., Kamholz J., and Scherer S.S. Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). J. Neuropathol. Exp. Neurol. 56 (1997) 811-821
35. Uceyler N., Kobsar I., Biko L., Ulzheimer J., Levinson S.R., Martini R., and Sommer C. Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy. J. Neurosci. Res. 84 (2006) 37-46
36. Zielasek J., Martini R., and Toyka K.V. Functional abnormalities in P0-deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 19 (1996) 946-952